AstraZeneca Heartburn Drug Wins New Approval
Posted on: Wednesday, 25 October 2006, 15:00 CDT
The FDA has approved a new formulation for AstraZeneca's prescription drug Nexium, used in the treatment of heartburn and gastric conditions.
The new Nexium formulation is an oral suspension product and will be an alternative to Nexium tablets. This new oral suspension version of Nexium contains esomeprazole, the same active ingredient used in the original capsules. The esomeprazole granules used in this formulation are mixed with water to form a suspension and are given by oral or gastric administration.
"Some patients with acid-related diseases have difficulties swallowing their oral medication when it is a solid pill," said Doug Levine, executive director for Nexium. "This new prescription option to swallow an oral suspension of Nexium or to have it administered via a stomach tube provides these patients with an alternative method of administration that they can take instead of the Nexium capsule."
The new formulation of Nexium will be available in the first quarter of 2007.
Nexium is approved for treating heartburn and other symptoms associated with acid reflux disease. Nexium is also indicated for reducing the risk of stomach ulcers developing among at risk patients on anti-inflammatory drug therapy.
Source: Datamonitor
Related Articles
- Walmart Pharmacists Prepare and Offer Tamiflu(R) for Oral Suspension for Children and Elderly at More Than 4,000 Locations
- Poniard Pharmaceuticals Announces Positive Preliminary Bioavailability Data From Ongoing Phase 1 Trial of Oral Picoplatin in Patients With Solid Tumors
- ARIAD Initiates Phase 3 'Succeed' Trial of Oral Deforolimus in Patients With Metastatic Sarcomas
- MGI PHARMA Announces Publication of Phase 3 Data for Saforis(TM) (Glutamine) Powder in UpTec(TM) for Oral Suspension in Cancer
- NovaDel Announces Positive Results From Pharmacokinetic Study of Improved Sumatriptan Oral Spray Formulation
- Lupin Announces Final FDA Approval of Cefdinir for Oral Suspension
- Par Pharmaceutical Receives Final Approval To Market Generic Cefzil(R) For Oral Suspension
- Teva Announces Approval of Cefprozil Tablets and Cefprozil for Oral Suspension USP
- Oral Solution Formulation of Namenda(R), the Only FDA-Approved Oral Solution for Moderate to Severe Alzheimer's Disease, Now Available
- European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (Posaconazole) Oral Suspension for Treatment of Invasive Fungal Infections
 |
 |
User Comments (0)
RSS Feeds